Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study
Work
Year: 2024
Type: article
Abstract: Background Targeting receptor-interacting serine/threonine protein kinase 1 could mitigate the devastating sequelae of the hyperinflammatory state observed in severe cases of COVID-19. This study exp... more
Source: Respiratory Research
Institutions Sanofi (France), Sanofi (United States), Sanofi (Germany), Center for Global Development, Hôpital Cochin
Cites: 37
Cited by: 6
Related to: 10
FWCI: 5.11
Citation percentile (by year/subfield): 99.99
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $2,440